Inherited diseases of the glomerular basement membrane

Nature Clinical Practice Nephrology

Volumn 4, Issue 1, 2008, Pages 24-37

  Gubler, Marie Claire ^a,b  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Alport syndrome; Glomerular basement membrane; Laminin; Nail patella syndrome; Type IV collagen

Indexed keywords

AGRIN; ANGIOTENSIN RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR ANTAGONIST; COLLAGEN; COLLAGEN TYPE 3; COLLAGEN TYPE 4; COLLAGEN TYPE 4 ALPHA3 ALPHA4 ALPHA5; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENTACTIN; FIBRONECTIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAMININ; LAMININ 521; METALLOPROTEINASE INHIBITOR; PROTEOHEPARAN SULFATE; UNCLASSIFIED DRUG;

ALPORT SYNDROME; AUTOSOMAL DOMINANT DISORDER; AUTOSOMAL RECESSIVE DISORDER; BIOACCUMULATION; BOWMAN CAPSULE; CLINICAL EXAMINATION; CLINICAL FEATURE; COL4A1 GENE; DISEASE COURSE; FAMILIAL BENIGN HEMATURIA; FECHTNER SYNDROME; FIBRONECTIN NEPHROPATHY; GENE; GENE AMPLIFICATION; GENETIC ANALYSIS; GENETIC DISORDER; GLOMERULOPATHY; GLOMERULUS BASEMENT MEMBRANE; HEMATURIA; HETEROZYGOSITY; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY FAILURE; LAMININ BETA 2 GENE; MUTATIONAL ANALYSIS; NAIL PATELLA SYNDROME; NEPHRITIS; NEPHROTIC SYNDROME; NONHUMAN; PATHOGENESIS; PIERSON SYNDROME; PRENATAL SCREENING; PRIORITY JOURNAL; REVIEW; X CHROMOSOME LINKED DISORDER;

ANIMALS; COLLAGEN TYPE III; COLLAGEN TYPE IV; FIBRONECTINS; GLOMERULAR BASEMENT MEMBRANE; HEMATURIA; HETEROZYGOTE; HUMANS; KIDNEY DISEASES; LAMININ; MUTATION; NAIL-PATELLA SYNDROME; NEPHRITIS, HEREDITARY; PHENOTYPE;

EID: 37349123995     PISSN: 17458323     EISSN: 17458331     Source Type: Journal    
DOI: 10.1038/ncpneph0671     Document Type: Review

References (115)

1. Timpl R (1989) Structure and biochemical activity of basement membrane proteins. Eur J Biochem 180: 487-502
2. Hudson BG et al. (2003) Alport's syndrome, Goodpasture's syndrome, and type IV collagen. N Engl J Med 348: 2543-2556
3. Soininen R et al. (1988) The structural genes for α1 and α2 chains of human type IV collagen are divergently encoded on opposite DNA strands and have an overlapping promoter region. J Biol Chem 263: 17217-17220
4. Mariyama M et al. (1992) Colocalization of the genes for the α3(IV) and α4(IV) chains of type IV collagen to chromosome 2 bands q35-q37. Genomics 13: 809-813
5. Leinonen A et al. (1994) Complete primary structure of the human type IV collagen α4(IV) chain: comparison with structure and expression of the other α(IV) chains. J Biol Chem 269: 26172-26177
6. Mariyama M et al. (1994) Complete primary structure of the human α3(IV) collagen chain: coexpression of the α3(IV) and α4(IV) collagen chains in human tissues. J Biol Chem 269: 23013-23017
7. Hostikka SL et al. (1990) Identification of a distinct type IV collagen α chain with restricted kidney distribution and assignment of its gene to the locus of X-linked Alport syndrome. Proc Natl Acad Sci USA 87: 1606-1610
8. Myers JC et al. (1990) Molecular cloning of α5(IV) collagen and assignment of the gene to the region of the X chromosome containing the Alport syndrome locus. Am J Hum Genet 46: 1024-1033
9. Sugimoto M et al. (1994) The genes COL4A5 and COL4A6, coding for basement membrane collagen chains α5(IV) and α6(IV), are located head-to-head in close proximity on human chromosome Xq22 and COL4A6 is transcribed from two alternative promoters. Proc Natl Acad Sci USA 91: 11679-11683
10. Miner JH and Sanes JR (1994) Collagen IV α3, α4, and α5 chains in rodent basal laminae: sequence, distribution, association with laminins, and developmental switches. J Cell Biol 127: 879-891
11. Kalluri R et al. (1997) Isoform switching of type IV collagen is developmentally arrested in X-linked Alport syndrome leading to increased susceptibility of renal basement membranes to endoproteolysis. J Clin Invest 99: 2470-2478
12. Cheong HI et al. (1994) Immunohistologic studies of type IV collagen in anterior lens capsules of patients with Alport syndrome. Lab Invest 70: 553-557
13. Cosgrove D et al. (1996) Immunohistochemical localization of basement membrane collagens and associated proteins in the murine cochlea. Hear Res 97: 54-65
14. Borza DB et al. (2001) The NC1 domain of collagen IV encodes a novel network composed of the α1, α2, α5, and α6 chains in smooth muscle basement membranes. J Biol Chem 276: 28532-28540
15. Peissel B et al. (1995) Comparative distribution of the α1(IVα5(IV), and α6(IV) collagen chains in normal human adult and fetal tissues and in kidneys from X-linked Alport syndrome patients. J Clin Invest 96: 1948-1957
16. Ninomiya Y et al. (1994) Differential expression of two basement membrane collagen genes, COL4A6 and COL4A5, demonstrated by immunofluorescence staining using peptide-specific monoclonal antibodies. J Cell Biol 130: 1219-1229
17. Yurchenco PD and Ruben GC (1987) Basement membrane structure in situ: evidence for lateral associations in the type IV collagen network. J Cell Biol 105: 2559-2568
18. Timpl R and Brown JC (1994) The laminins. Matrix Biology 14: 275-281
19. Miner JH (1999) Renal basement membrane components. Kidney Int 56: 2016-2024
20. Aumailley M et al. (2005) A simplified laminin nomenclature. Matrix Biol 24: 326-332
21. Katz A et al. (1991) Renal entactin (nidogen): isolation, characterization and tissue distribution. Kidney Int 10: 643-652
22. Groffen AJ et al. (1998) Agrin is a major heparan sulfate proteoglycan in the human glomerular basement membrane. J Histoch Cytoch 46: 19-27
23. Alport AC (1927) Hereditary familial congenital haemorrhagic nephritis. Br Med J 1: 504-506
24. Atkin CL et al. (1988) Alport syndrome. In Diseases of the Kidney, edn 4, 617-641 (Eds Schrier RW and Gottschalk CW) Boston: Little, Brown, and Company
25. Flinter FA et al. (1988) Genetic of classic Alport's syndrome. Lancet 2: 1005-1007
26. Gubler M et al. (1981) Alport's syndrome: a report of 58 cases and a review of the literature. Am J Med 70: 493-505
27. Kashtan CE and Michael AF (1993) Alport syndrome: from bedside to genome to bedside. Am J Kidney Dis 22: 627-640
28. Pajari H et al. (1996) Alport's syndrome in 78 patients: epidemiological and clinical study. Acta Paediatr 85: 1300-1306
29. Nielsen CE (1977) Lenticonus anterior and Alport's syndrome. Acta Ophthalmol 56: 518-530
30. Polack BCP and Hogewind BL (1977) Macular lesions in Alport's disease. Am J Ophthalmol 84: 533-535
31. Perrin D et al. (1980) Perimacular changes in Alport's syndrome. Clin Nephrol 13: 163-167
32. Rhys C et al. (1997) Recurrent corneal erosion associated with Alport's syndrome. Kidney Int 52: 208-211
33. Hinglais N et al. (1972) Characteristic ultrastructural lesion of the glomerular basement membrane in progressive hereditary nephritis (Alport's syndrome). Lab Invest 27: 473-487
34. Spear GS and Slusser RJ (1972) Alport's syndrome: emphasizing electron microscopic studies of the glomerulus. Am J Pathol 69: 213-222
35. Churg J and Sherman RL (1973) Pathologic characteristics of hereditary nephritis. Arch Pathol 95: 374-379
36. Gubler MC et al. (2006) Alport syndrome, familial benign hematuria, nail-patella syndrome and type III collagen nephropathy. In Heptinstall's Pathology of the Kidney, edn 6, 487-515 (Eds Jennette JC et al.) Baltimore: Lippincott, Williams & Wilkins
37. Jais JP et al. (2000) X-linked Alport syndrome: natural history in 195 families and genotype-phenotype correlations in males. J Am Soc Nephrol 11: 649-657
38. Barker DF et al. (1990) Identification of mutations in the COL4A5 collagen gene in Alport syndrome. Science 248: 1224-1227
39. Mochizuki T et al. (1994) Identification of mutations in the α3(IV) and α4(IV) collagen genes in autosomal recessive Alport syndrome. Nat Genet 8: 77-82
40. Gross O et al. (2002) Meta-analysis of genotype-phenotype correlation in X-linked Alport syndrome: impact on clinical counseling. Nephrol Dial Transplant 17: 1218-1227
41. Jais JP et al. (2003) X-Linked Alport syndrome: natural history and genotype-phenotype correlations in girls and women belonging to 195 families: a "European Community Alport Syndrome Concerted Action" study. J Am Soc Nephrol 14: 2603-2610
42. Tryggvason K et al. (1993) Molecular genetics of Alport syndrome. Kidney Int 43: 38-44
43. Lemmink HH et al. (1997) The clinical spectrum of type IV collagen mutations. Hum Mutat 9: 477-499
44. Antignac C et al. (1994) Deletions in the COL4A5 collagen gene in X-linked Alport syndrome: characterization of the pathological transcripts in nonrenal cells and correlation with diseases expression. J Clin Invest 93: 1195-1207
45. Renieri A et al. (1995) Major COL4A5 gene rearrangements in patients with juvenile type Alport syndrome. Am J Med Genet 59: 380-385
46. Knebelmann B et al. (1996) Spectrum of mutations in the COL4A5 gene in X-linked Alport syndrome. Am J Hum Genet 59: 1221-1232
47. Kawai S et al. (1996) The COL4A5 gene in Japanese Alport syndrome patients: spectrum of mutations of all exons. Kidney Int 49: 814-822
48. Martin P et al. (1998) High mutation detection rate in the COL4A5 collagen gene in suspected Alport syndrome using PCR and direct DNA sequencing. J Am Soc Nephrol 9: 2291-2301
49. Inoue Y et al. (1999) Detection of mutations in the COL4A5 gene in over 90% of male patients with X-linked Alport's syndrome by RT-PCR and direct sequencing. Am J Kidney Dis 34: 854-862
50. Barker DF et al. (1996) A mutation causing Alport syndrome with tardive hearing loss is common in the western United States. Am J Hum Genet 58: 1157-1165
51. Antignac C et al. (1992) Alport syndrome and diffuse leiomyomatosis: deletions in the 5′ end of the COL4A5 collagen gene. Kidney Int 42: 1178-1183
52. Zhou J et al. (1993) Deletion of the paired α5(IV) and α6(IV) collagen genes in inherited smooth muscle tumors. Science 261: 1167-1169
53. Heidet L et al. (1995) Deletions of both α5(IV) and α6(IV) collagen genes in Alport syndrome and in smooth muscle cell proliferation associated with Alport syndrome. Hum Mol Genet 4: 99-108
54. Vitelli F et al. (1999) Identification and characterization of a highly conserved protein absent in the Alport syndrome (A), mental retardation (M), midface hypoplasia (M), and elliptocytosis (E) contiguous gene deletion syndrome (AMME). Genomics 55: 335-340
55. Nakanishi K et al. (1994) Immunohistochemical study of α1-5 chains of type IV collagen in hereditary nephritis. Kidney Int 46: 1413-1421
56. Mazzucco G et al. (1998) Ultrastructural and immunohistochemical findings in Alport's syndrome: a study of 108 patients from 97 Italian families with particular emphasis on COL4A5 gene mutation correlations. J Am Soc Nephrol 9: 1023-1031
57. Kashtan C and Kim Y (1992) Distribution of the α1 and α2 chains of collagen IV and of collagens V and VI in Alport syndrome. Kidney Int 42: 115-126
58. Lemmink HH et al. (1994) Mutations in the type IV collagen α3 (COL4A3) gene in autosomal recessive Alport syndrome. Hum Mol Genet 3: 1269-1273
59. Boye E et al. (1998) Determination of the genomic structure of the COL4A4 gene and of novel mutations causing autosomal recessive Alport syndrome. Am J Hum Genet 63: 1329-1340
60. Heidet L et al. (2001) Structure of the human type IV collagen gene COL4A3 and mutations in autosomal Alport syndrome. J Am Soc Nephrol 12: 97-106
61. Longo I et al. (2006) Autosomal recessive Alport syndrome: an in-depth clinical and molecular analysis of five families. Nephrol Dial Transplant 21: 665-671
62. Gubler MC et al. (1995) Autosomal recessive Alport syndrome: immunohistochemical study of type IV collagen chain distribution. Kidney Int 47: 1142-1147
63. Rogers PW et al. (1973) Familial benign essential hematuria. Arch Intern Med 131: 257-262
64. Van der Loop FT et al. (2000) Autosomal dominant Alport syndrome caused by a COL4A3 splice site mutation. Kidney Int 58: 1870-1875
65. Pescucci C et al. (2004) Autosomal-dominant Alport syndrome: natural history of a disease due to COL4A3 or COL4A4 gene. Kidney Int 65: 1598-1603
66. Savige J et al. (2003) Thin basement membrane nephropathy. Kidney Int 64: 1169-1178
67. Tryggvason K and Patrakka J (2006) Thin basement membrane nephropathy. J Am Soc Nephrol 17: 813-822
68. Kashtan CE (1998) Alport syndrome and thin glomerular basement membrane disease. J Am Soc Nephrol 9: 1736-1750
69. Lemmink HH et al. (1996) Benign familial hematuria due to mutation of the type IV collagen α4 chain. J Clin Invest 98: 1114-1118
70. Buzza M et al. (2001) Segregation of hematuria in thin basement membrane disease with haplotypes at loci for Alport syndrome. Kidney Int 59: 1670-1675
71. Badenas C et al. (2002) Mutations in the COL4A4 and COL4A3 genes cause familial benign hematuria. J Am Soc Nephrol 13: 1248-1254
72. Piccini M et al. (1999) Evidence for genetic heterogeneity in benign familial hematuria. Am J Nephrol 19: 464-467
73. Longo I et al. (2002) From benign familial hematuria to autosomal dominant or recessive Alport syndrome. Kidney Int 61: 1947-1956
74. Torra R et al. (2004) Collagen type IV (α3-α4) nephropathy from isolated haematuria to renal failure. Nephrol Dial Transplant 19: 2429-2432
75. Seri M et al. (2000) Mutations in MYH9 result in the May-Hegglin anomaly, and Fechtner and Sebastian syndromes: the May-Hegglin/Flechtner Syndrome Consortium. Nat Genet 26: 103-105
76. Tazón-Vega B et al. (2007) Genetic testing for X-linked Alport syndrome by direct sequencing of COL4A5 cDNA from hair root RNA samples. Am J Kidney Dis 50: 257.e1-257.e14
77. -/- mice. Am J Pathol 163: 1633-1644
78. Sugimoto H et al. (2006) Bone-marrow-derived stem cells repair basement membrane collagen defects and reverse genetic kidney disease. Proc Natl Acad Sci USA 103: 7321-7326
79. Prodromidi EI et al. (2006) Bone marrow derived-cells contribute to podocyte regeneration and amelioration of renal disease in a mouse model of Alport syndrome. Stem Cells 24: 2448-2455
80. Gross O et al. (2004) Antifibrotic, nephroprotective potential of ACE inhibitor vs AT1 antagonist in a murine model of renal fibrosis. Nephrol Dial Transplant 67: 1716-1723
81. Ninichuk V et al. (2005) Delayed chemokine receptor 1 blockade prolongs survival in collagen 4A3-deficient mice with Alport disease. J Am Soc Nephrol 16: 977-985
82. Koepke Ml et al. (2007) Nephroprotective effect of the HMG-CoA-reductase inhibitor cerivastatin in a mouse model of progressive renal fibrosis in Alport syndrome. Nephrol Dial Transplant 22: 1062-1069
83. Zeisberg M et al. (2006) Stage-specific action of matrix metalloproteinases influences progressive hereditary kidney disease. PloS Med 3: e100
84. Zhang KW et al. (2007) Do mutations in COL4A1 or COL4A2 cause thin basement membrane nephropathy (TBMN)? Pediatr Nephrol 22: 645-651
85. Gould DB et al. (2005) Mutations in Col4a1 cause perinatal cerebral hemorrhage and porencephaly. Science 308: 1167-1171
86. Van der Knaap MS et al. (2006) Neonatal porencephaly and adult stroke related to mutations in collagen IV A1. Ann Neurol 59: 504-511
87. Plaisier E et al. Role of COL4A1 mutations in the hereditary angiopathy with nephropathy, aneurysm and cramps (HANAC) syndrome. N Engl J Med, in press
88. Pierson M et al. (1963) Une curieuse association malformative congénitale et familiale atteignant l'oeil et le rein. J Génét Hum 12: 184-213
89. Zenker M et al. (2004) Human laminin β2 deficiency causes congenital nephrosis with mesangial sclerosis and distinct eye abnormalities (Pierson syndrome). Hum Mol Genet 13: 2625-2632
90. Hasselbacher K et al. (2006) Recessive missense mutations in LAMB2 expand the clinical spectrum of LAMB2-associated disorders. Kidney Int 70: 1008-1012
91. Noakes PG et al. (1995) The renal glomerulus of mice lacking s-laminin/laminin β2: nephrosis despite molecular compensation by laminin β1. Nat Genet 10: 400-406
92. -/- mice, implicating the glomerular basement membrane as an albumin barrier. J Clin Invest 16: 2272-2279
93. Sweeney E et al. (2003) Nail patella syndrome: a review of the phenotype aided by developmental biology. J Med Genet 40: 153-162
94. Bongers EM et al. (2005) Genotype-phenotype studies in nail-patella syndrome show that LMX1B mutation location is involved in the risk of developing nephropathy. Eur J Hum Genet 13: 1019-1024
95. Heidet L et al. (2003) In vivo expression of putative LMX1B targets in nail-patella syndrome kidneys. Am J Pathol 163: 145-155
96. Ben Bassat M et al. (1971) The glomerular basement membrane in the nail-patella syndrome. Arch Pathol 92: 350-355
97. Hoyer JR et al. (1972) Renal disease in nail-patella syndrome: clinical and morphologic studies. Kidney Int 2: 231-238
98. Bennet WM et al. (1973) The nephropathy of the nail-patella syndrome: clinicopathologic analysis of 11 kindreds. Am J Med 54: 304-319
99. Vollrath D et al. (1998) Loss-of-function mutations in the LIM-homeodomain gene, LMX1B, in nail patella syndrome. Hum Mol Genet 7: 1091-1098
100. Chen H et al. (1998) Limb and kidney defects in Lmx1b mutant mice suggest an involvement of LMX1B in human nail patella syndrome. Nat Genet 19: 51-55
101. Dreyer SD et al. (1998) Mutations in LMX1B cause abnormal skeletal patterning and renal dysplasia in nail patella syndrome. Nat Genet 19: 47-50
102. Rohr C et al. (2002) The LIM-homeodomain transcription factor Lmx1b plays a crucial role in podocytes. J Clin Invest 109: 1073-1082
103. Miner JH et al. (2002) Transcriptional induction of slit diaphragm genes by Lmx1b is required in podocyte differentiation. J Clin Invest 109: 1065-1072
104. Morello R et al. (2001) Regulation of glomerular basement membrane collagen expression by LMX1B contributes to renal disease in nail patella syndrome. Nat Genet 27: 205-208
105. Salcedo JR (1984) An autosomal recessive disorder with glomerular basement membrane abnormalities similar to those seen in the nail-patella syndrome: report of a kindred. Am J Med Genet 19: 579-584
106. Arakawa M and Yamanaka N (1991) Collagenofibrotic glomerulonephropathy. London: Nishimura & Smith-Gordon
107. Gubler MC et al. (1993) Collagen type III glomerulopathy: a new type of hereditary nephropathy. Pediatr Nephrol 7: 354-360
108. Imbasciati E et al. (1991) Collagen type III glomerulopathy: a new idiopathic glomerular disease. Am J Nephrol 11: 422-429
109. Vogt BE et al. (1995) Inherited factor H deficiency and collagen type III glomerulopathy. Pediatr Nephrol 9: 11-15
110. Strom EH et al. (1995) Glomerulopathy associated with predo minant fibronectin deposits: a newly recognized hereditary disease. Kidney Int 48: 163-170
111. Assmann KJM et al. (1995) Familial glomerulonephritis characterized by massive deposits of fibronectin. Am J Kidney Dis 25: 781-791
112. Hildebrandt F et al. (1996) Glomerulopathy associated with predominant fibronectin deposits: exclusion of the genes for fibronectin, villin, and desmin. Am J Med Genet 63: 323-327
113. Zhang Z et al. (1997) Severe fibronectin-deposit renal glomerular disease in mice lacking uteroglobin. Science 276: 1408-1412
114. Volmer M et al. (1998) Exclusion of the uteroglobin gene as a candidate for fibronectin glomerulopathy (GFND). Nephrol Dial Transplant 13: 2417-2418
115. Vollmer M et al. (2000) Molecular cloning of the critical region for glomerulopathy with fibronectin deposits and evaluation of candidated genes. Genomics 68: 127-135